Latest Nasdaq News

Telix Pharmaceuticals returned to profit in H1 2026, driven by strong U.S. sales of Illuccix and Gozellix, a $40 million upfront from Regeneron collaboration, and expanded R&D investment.

European Lithium and Critical Metals Corp have amended their merger terms to replace a fixed share exchange ratio with a floating ratio tied to Critical Metals' NASDAQ share price, potentially increasing shareholder value amid ongoing merger progress.

JPMorgan Asset Management confirms final cash distributions and reinvestment prices for six Equity Premium Income ETFs for August 2026, following recent structural changes in four funds.

Almonty Industries launches a US$300 million share repurchase program over three years, aiming to capitalise on undervalued shares ahead of full capacity at its Sangdong mine.

Mesoblast has treated 350 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain linked to degenerative disc disease, setting the stage for top-line results in mid-2027.

Jindalee Lithium's US arm has cleared the last regulatory hurdle to begin a critical Phase 1 drilling program at the McDermitt Lithium Project, aiming to upgrade resource confidence and provide key data for project feasibility.

Jindalee Lithium has taken another regulatory step by filing an amended Form S-4 with the US SEC, progressing its plan to spin out US lithium assets via US Elemental and list on NASDAQ.

Almonty Industries posted a striking turnaround in Q2 2026, driven by soaring tungsten prices, ramping Sangdong Mine operations, and a major $800 million convertible notes raise.

Alterity Therapeutics has won a new US composition of matter patent for its lead drug ATH434, extending intellectual property protection to at least 2045 and boosting its commercial potential ahead of Phase 3 trials in Multiple System Atrophy.

Anteris Technologies posted a $51.7 million loss in H1 2026 amid ramped-up R&D and clinical trial activity, supported by a $320 million capital raise and Medicare reimbursement for its DurAVR heart valve trial.

News Corp posted a 7% revenue increase to $9.028 billion in fiscal 2026, driven by gains across its key segments, while net income attributable to stockholders fell 51% due to absence of prior discontinued operations income.

Elevra Lithium has divested its Western Australian pegmatite rights at Tabba Tabba to Wildcat Resources for $16 million plus royalties, sharpening its focus on North American lithium growth.